Grass may transfer genes from their neighbors in the same way genetically modified crops are made, a new study has revealed.
Research, led by the University of Sheffield, is the first to show the frequency at which grasses incorporate DNA from other species into their genomes through a process known as lateral gene transfer.
The stolen genetic secrets give them an evolutionary advantage by allowing them to grow faster, bigger or stronger and adapt to new environments quicker.
Tina Woods, serving as Healthy Longevity Champion for the National Innovation Center for Aging, sets forth her vision for a blueprint for healthy longevity for all. Her emphasis is on reaping the “longevity dividend” and achieving five additional years of healthy life expectancy while reducing health and wellbeing inequality. Woods elaborates on the role of emerging technologies like AI, machine learning, and advanced data analysis in comprehending and influencing biological systems related to aging. She also underscores the crucial role of lifestyle changes and the consideration of socio-economic factors in increasing lifespan. The talk also explores the burgeoning field of emotion AI and its application in developing environments for better health outcomes, with a mention of “Longevity Cities,” starting with a trial in Newcastle. In closing, Woods mentions the development of a framework for incentivizing businesses through measurement of their contribution to health in three areas: workforce health, consumer health through products and services, and community health. Woods envisions a future where businesses impacting health negatively are disincentivized, and concludes with the hope that the UK’s healthy longevity innovation mission can harness longevity science and data innovation to improve life expectancy.
00:00:00 — Introduction, National Innovation Center for Aging.
00:00:56 — Discussion on stagnating life expectancy and UK’s life sciences vision.
00:03:50 — Technological breakthroughs (including AI) in analyzing biological systems.
00:06:22 — Understanding what maintains health & wellbeing.
00:08:30 — Hype, hope, important of purpose.
00:10:00 — Psychological aging and “brain capital.“
00:13:15 — Ageism — a barrier to progress in the field of aging.
00:15:46 — Health data, AI and wearables.
00:18:44 — Prevention is key, Health is an asset to invest in.
00:19:13 — Longevity Cities.
00:21:19 — Business for Health and industry incentives.
00:23:13 — Closing.
About the Speaker:
Tina Woods is a social entrepreneur and system architect with a focus on health innovation at the intersection of science, technology, policy, and investment. She is the Founder and CEO of Collider Health and Business for Health, driving systemic change for better health through these platforms. She contributes to key UK health strategies and initiatives, like UKRI’s Healthy Ageing Industrial Strategy, and served as the Healthy Longevity Champion for the National Innovation Centre for Ageing. Woods has made significant contributions to AI in health and care, co-leading the Quantum Healthy Longevity Innovation Mission and authoring the book, “Live Longer with AI.” Previously, she served as the director of the All Party Parliamentary Group for Longevity secretariat. Woods is also the CEO & Founder of Collider Science, a social enterprise that encourages young people’s interest in science and technology. She holds a degree in genetics from Cornell University and an MBA from Bayes Business School in London.
FOLLOW US
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀
https://www.lifespan.io.
https://www.facebook.com/lifespanio.
https://www.instagram.com/lifespan.io/
HOW CAN YOU SUPPORT US?
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀
Lifespan.io, a 501©(3) nonprofit organization.
► Support us with monthly donations by becoming a Lifespan Hero: https://www.lifespan.io/hero.
► Subscribe: https://www.youtube.com/user/LifespanIO
► Learn more, and help us: https://www.lifespan.io.
#Longevity #AI #Health #EARD
Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD
Discount Links:
NAD+ Quantification: https://www.jinfiniti.com/intracellular-nad-test/
Use Code: ConquerAging At Checkout.
Green Tea: https://www.ochaandco.com/?ref=conqueraging.
Oral Microbiome: https://www.bristlehealth.com/?ref=michaellustgarten.
Epigenetic Testing: Trudiagnostic.pxf.io/R55XDv.
Use Code: CONQUERAGING
At-Home Blood Testing: https://getquantify.io/mlustgarten.
The investigators carried out animal trials with the engineered AsCas12f system, partnering it with other genes and administering it to live mice. The encouraging results indicated that engineered AsCas12f has the potential to be used for human gene therapies, such as treating hemophilia.
The team discovered numerous potentially effective combinations for engineering an improved AsCas12f gene-editing system, and acknowledged the possibility that the selected mutations may not have been the most optimal of all the available mixes. As a next step, computational modeling or machine learning could be used to sift through the combinations and predict which might offer even better improvements.
And as the authors noted, by applying the same approach to other Cas enzymes, it may be possible to generate efficient genome-editing enzymes capable of targeting a wide range of genes. “The compact size of AsCas12f offers an attractive feature for AAV-deliverable gRNA and partner genes, such as base editors and epigenome modifiers. Therefore, our newly engineered AsCas12f systems could be a promising genome-editing platform … Moreover, with suitable adaptations to the evaluation system, this approach can be applied to enzymes beyond the scope of genome editing.”
Venture Investing To Catalyze The Next Generation Of Founder-Led, Longevity Biotech Companies — Dr. Alex Colville, Ph.D., Co-Founder and General Partner — age1.
Dr. Alex Colville, Ph.D. is Co-Founder and General Partner of age1 (https://age1.com/), a venture capital firm focused on catalyzing the next generation of founder-led, longevity biotech companies, with a strategy of building a community of visionaries advancing new therapeutics, tools, and technologies targeting aging and age-related diseases.
With a recent initial closing of US$35 million, age1 will be focusing on founders and companies at the earliest stages of first-money in, pre-seed and seed funding, and is resourced to continue to support companies through later rounds.
Dr. Colville previously established the biotech arm of Starbloom Capital and served as founding Chief of Staff of Amaranth Foundation, where he led: the foundation’s support of skilled researchers and ambitious moonshot projects in the longevity field, and helped to advance their lobbying efforts; the TIME Initiative (a group with mission to activate undergraduate students’ interest in aging biology); the Marine Biology Laboratory Biology of Aging Summer Course, among other programs.
Dr. Colville completed his Ph.D. in Genetics at Stanford University studying the biology of aging in Dr. Thomas Rando’s lab while consulting for several family offices, the R&D team of Rubedo Life Sciences, and the business development team of Maze Therapeutics. Prior to his Ph.D., while at Northeastern University completing his Bachelor of Science (B.S.) in Chemical Engineering with a Minor in Biochemical Engineering, he advised pharma companies as a management consultant at Putnam Associates, a boutique life sciences consulting firm.
Professor René Ketting’s team at the Institute of Molecular Biology (IMB) in Mainz, Germany, along with Dr. Sebastian Falk’s group at the Max Perutz Labs in Vienna, Austria, have discovered a new enzyme, PUCH, which plays a key role in preventing the spread of parasitic DNA
DNA, or deoxyribonucleic acid, is a molecule composed of two long strands of nucleotides that coil around each other to form a double helix. It is the hereditary material in humans and almost all other organisms that carries genetic instructions for development, functioning, growth, and reproduction. Nearly every cell in a person’s body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA).
George Church at his most optimistic. June 1, 2022.
Dr George Church talks about combination therapies for age reversal, recently published papers from his lab and expresses his wish on developing inexpensive gene therapies like vaccine that can be equitably distributed to human.
Dr George Church is the Robert Winthrop Professor of Genetics at Harvard Medical School, a Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT), and a core faculty member of the Wyss Institute.
Same as Dr David Sinclair, Dr George Church currently runs the Church Lab at Harvard Medical School. Both labs collaborate many projects together especially on age reversal topics. Dr Church also directs the Personal Genome Project, a long-term cohort study that allows scientists to connect human genetic information (human DNA sequence, gene expression, associated microbial sequence data, and more) with human trait information (medical information, biospecimens, and physical traits) and environmental exposures.
DISCLAIMER: Please note that none of the information in this video constitutes health advice or should be substituted in lieu of professional guidance. The video content is purely for informational purposes.